NCT07061639View on ClinicalTrials.gov

A Study of QLS5133 Monotherapy in Advanced Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

April 30, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

QLS5133

antibody drug conjugate (ADC)

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT07061639 - A Study of QLS5133 Monotherapy in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter